CDPF1 (UPF0595) as a Drug Target and Biomarker for Proliferative Disorders

Target Name: CDPF1

NCBI ID: G150383

CDPF1

CDPF1 (UPF0595) as a Drug Target and Biomarker for Proliferative Disorders

Abstract:

CDPF1 (UPF0595) is a protein that has been identified as a potential drug target and biomarker for proliferative disorders. Its expression has been observed in various tissues and has been associated with the development and progression of many diseases, including cancer. This article reviews the current research on CDPF1 and its potential as a drug target and biomarker.

Introduction:

Proliferative disorders are a group of diseases that are characterized by the rapid and uncontrolled growth of cells in the body. These disorders include cancer, sarcoma, and neurofibromatosis, among others. The development and progression of these disorders is driven by the continuous growth and division of cells, which leads to the formation of tumors, tumors, and other abnormal cell populations.

CDPF1: A Potential Drug Target and Biomarker

CDPF1 is a protein that has been identified as a potential drug target and biomarker for proliferative disorders. Its expression has been observed in various tissues, including cancer cells, and has been associated with the development and progression of many diseases.

CDPF1 is a 22kDa protein that is expressed in various tissues, including muscle, pancreas, and brain. It is characterized by a unique N-terminal domain that consists of a single amino acid, which is known as HNW. The HNW domain is responsible for the protein's stability and functions as a scaffold.

CDPF1 has been shown to be involved in many cellular processes, including cell adhesion, migration, and the regulation of cell cycle. It has also been shown to be involved in the development and progression of various diseases, including cancer.

CDPF1 as a Drug Target:

CDPF1 has been identified as a potential drug target for cancer due to its involvement in cell adhesion and migration. Many studies have shown that CDPF1 is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. It has also been shown to play a role in the regulation of cell cycle, which is a critical step in the development of cancer.

CDPF1 has been shown to interact with several drug targets that are involved in cancer treatment. For example, it has been shown to interact with the drug inhibitor PD-L1, which has been shown to have anti-cancer effects. Additionally, CDPF1 has been shown to interact with the drug inhibitor IMGN3023, which has also been shown to have anti-cancer effects.

CDPF1 as a Biomarker:

CDPF1 has also been identified as a potential biomarker for cancer due to its expression in various types of cancer. Many studies have shown that CDPF1 is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that CDPF1 could be used as a biomarker for cancer, particularly in cases where there is a lack of other biomarkers.

CDPF1 has been shown to have a strong positive correlation with the survival of cancer patients. For example, a study published in the journal Cancer showed that higher levels of CDPF1 were associated with a poor prognosis in patients with pancreatic ductal adenocarcinoma, a type of cancer.

Conclusion:

In conclusion, CDPF1 is a protein that has been identified as a potential drug target and biomarker for proliferative disorders. Its expression has been observed in various tissues and has been associated with the development and progression of many diseases, including cancer. Further research is needed to fully understand the role of CDPF1

Protein Name: Cysteine Rich DPF Motif Domain Containing 1

The "CDPF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDPF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets